Brief: SynAct Says Approval From Swedish Medical Product Agency, Swedish Ethical Review Authority On Phase IIa Study With AP1189

SynAct Pharma AB

11/11/2019 18:36

Nov 11 (Reuters) - SynAct Pharma AB  SYNACT.TE :
    * SYNACT RECEIVES APPROVAL FROM THE SWEDISH MEDICAL PRODUCT
AGENCY
AND THE SWEDISH ETHICAL REVIEW AUTHORITY REGARDING THE CLINICAL
PHASE IIA STUDY WITH AP1189
    * SYNACT PHARMA AB - PHASE IIA STUDY CURRENTLY ONGOING ON
CLINICAL
SITES IN DENMARK FOLLOWING APPROVAL BY DANISH MEDICINES AGENCY
IN JUNE 2019
    * SYNACT PHARMA - CLINICAL TRIAL APPLICATION FILED TO
NORWEGIAN
MEDICINES AGENCY, NORWEGIAN NATIONAL COMMITTEE FOR MEDICAL &
HEALTH RESEARCH ETHICS

Source text for Eikon:  ID:nWkrb1Q7MJ 
Further company coverage:  SYNACT.TE 

 ((Reuters.Briefs@thomsonreuters.com;))